GlassScriptPhysician profile
Rada Norov
NPI 1326435512
$4,421.71
in general payments reported to CMS, 2019-2025
40 companies · $916 in 2025
The $916 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $271 · 2021: $779 · 2022: $363 · 2023: $447 · 2024: $836 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $838.86 | 2021-2024 | Trulance, Xifaxan |
| Abbvie INC. | $625.32 | 2019-2025 | |
| Lilly USA, LLC | $320.86 | 2019-2024 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $283.76 | 2019-2025 | |
| Viiv Healthcare Company | $275.77 | 2019-2020 | |
| Axsome Therapeutics, INC. | $266.50 | 2025 | Auvelity |
| Novo Nordisk INC | $220.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $211.20 | 2019-2025 | Verquvo, Steglatro |
| Glaxosmithkline, LLC. | $123.07 | 2024-2025 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $116.19 | 2024-2025 | Gemtesa |
| Qol Medical, LLC | $108.75 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $92.41 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Myovant Sciences INC. | $81.73 | 2021-2022 | |
| Pfizer INC. | $79.96 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $60.64 | 2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rada Norov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.